Corrigendum: Usefulness and Potential Pitfalls of Long-Acting Growth Hormone Analogues (Front. Endocrinol., (2021), 12, (637209), 10.3389/fendo.2021.637209)

Kevin C.J. Yuen, Bradley S. Miller, Cesar L. Boguszewski, Andrew R. Hoffman

Research output: Contribution to journalComment/debatepeer-review

Abstract

ERROR IN TABLE 1, 5TH COLUMN, 19TH ROW In the original article, there was a mistake in Table 1 as published. In Table 1, 5th column, 19th row, the company “Alteogen” under the “Current Status” column was incorrectly stated that the company was “bankrupt in 2009”. This statement is incorrect as the company remains a currently viable bio-tech company globally. The authors apologize for this inadvertent error with the statement and a modified Table 1 is provided below, where the statement “bankrupt in 2009” is now deleted. This new table does not change the scientific conclusions of the article in any way. The original article has been updated.

Original languageEnglish (US)
Article number705241
JournalFrontiers in Endocrinology
Volume12
DOIs
StatePublished - Jun 28 2021

Bibliographical note

Funding Information:
Acknowledgements--We are thankful to A. Rusu and V. Atultanova for help with the scanning and computer treatment of the EPR spectra. We also acknowledge the financial support of the Estonian Science Foundation.

Publisher Copyright:
© 2021 Yuen, Miller, Boguszewski and Hoffman.

Keywords

  • adults
  • children
  • growth hormone deficiency
  • growth hormone replacement
  • long-acting growth hormone
  • treatment adherence

PubMed: MeSH publication types

  • Published Erratum

Fingerprint

Dive into the research topics of 'Corrigendum: Usefulness and Potential Pitfalls of Long-Acting Growth Hormone Analogues (Front. Endocrinol., (2021), 12, (637209), 10.3389/fendo.2021.637209)'. Together they form a unique fingerprint.

Cite this